How is BPC-157 dosed and mixed?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds BPC-157 and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
A review describes off-label BPC-157 doses as typically 200 to 500 µg a day under the skin or by mouth, extrapolated informally from rodent doses without formal allometric scaling,1 and 500 mcg is the dose most often logged in Milligram (49%).11
The guide's example
500 mcg of BPC-157 from a 10 mg vial mixed with 2 mL is 10 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water | 3 mL of water |
|---|---|---|---|
| 5 mg17% set up11 | 5 mg/mL: 250 mcg is 5 units, 500 mcg is 10 units | 2.5 mg/mL: 250 mcg is 10 units, 500 mcg is 20 units | 1.667 mg/mL: 250 mcg is 15 units, 500 mcg is 30 units |
| 10 mg69% set up11 | 10 mg/mL: 250 mcg is 2.5 units, 500 mcg is 5 units | 5 mg/mL: 250 mcg is 5 units, 500 mcg is 10 units | 3.333 mg/mL: 250 mcg is 7.5 units, 500 mcg is 15 units |
| 20 mg8% set up11 | 20 mg/mL: 250 mcg is 1.3 units, 500 mcg is 2.5 units | 10 mg/mL: 250 mcg is 2.5 units, 500 mcg is 5 units | 6.667 mg/mL: 250 mcg is 3.8 units, 500 mcg is 7.5 units |
Most often logged by Milligram users: 500 mcg, 49% logged.11
Mixing a vial and reading units
500 mcg of BPC-157 from a 10 mg vial mixed with 2 mL is 10 units on a U-100 syringe.
41% set up 10 mg + 2 mL11
Of the people who set up a BPC-157 vial in Milligram, 69% logged 10 mg, 17% 5 mg and 8% 20 mg.11 The mix most often set up was 10 mg with 2 mL (41%).11 Of the people who logged a draw, 40% set up 500 mcg at 10 units and 8% 500 mcg at 20 units.11 FDA's briefing gives the water solubility of BPC-157 free base as 5 mg/mL and names no diluent for mixing; one product it describes is a 10 mg per 5 mL injection kit sold for self-administration at home, and the mixing guide covers the steps.2 FDA gives the same 5 mg/mL for the acetate; the table's more concentrated cells sit above the water solubility FDA states.2
What reviews, trials and logs give for dose
A DailyMed search for BPC-157 returned no product label, and FDA's briefing states there is no approved product containing BPC-157-related substances in any country at this time.32 None of the human studies or registered trials reviewed here gives a stepped schedule. FDA says the human studies it found were short, small and tested doses likely exploratory in nature.2
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| NCT02637284 (start 2015), oral tablets | 1 mg tablets or placebo: a single dose of 1, 3 or 6 tablets (phase 1a), or 3 tablets three times daily (phase 1b); status unknown, no results posted42 | 42 healthy volunteers aged 18 to 35 (estimated) | Single dose (phase 1a); 2 weeks (phase 1b) |
| Veljaca et al., enema study | Up to 2 mg/kg rectal enema once daily, or placebo2 | 24 healthy people on BPC-157 (32 randomised) | 8 days |
| Ruenzi et al., enema trial | 80 mg rectal enema once daily, or placebo2 | 53 people with mild to moderate ulcerative colitis randomised 1:1 (about 26 on BPC-157) | 2 weeks |
| Lee and Padgett, knee pain chart review | 2-4 mg injected into the knee joint, BPC-157 alone or combined with TB4; the dose is FDA's summary, as the paper gives none25 | 17 people with knee pain (16 reached; 12 had BPC-157 alone, 4 with TB4) | 1-2 doses |
| Lee et al., interstitial cystitis pilot | 10 mg in total, injected around the bladder in one procedure62 | 12 women with interstitial cystitis, aged 39 to 76 | One procedure |
| Lee and Burgess, intravenous pilot | 10 mg on day 1 and 20 mg on day 2, each in 250 cc of normal saline infused over one hour72 | 2 healthy adults, each given intravenous BPC-157 before | Two days |
| NCT07752381, gummies | 500 µg per serving, two gummies daily by mouth, as a dietary supplement with no comparator group8 | 40 physically active adults | 8 weeks |
Two registered trials plan daily BPC-157 doses under the skin without stating the dose given: NCT07437547, recruiting, gives BPC-157 or placebo once daily for 14 days to people with a grade II hamstring strain (120 people estimated), and in NCT07803250, not yet recruiting, participants give themselves BPC-157 or saline daily for 90 days after rotator cuff repair (30 estimated in the enrollment field, twenty in the summary).910
In Milligram, 49% of people logged a 500 mcg dose and 18% logged 250 mcg.11 By unit, 71% logged mcg, 24% mg and 5% IU.11
How long BPC-157 keeps before and after mixing
FDA's briefing reports, citing a reference, that lyophilized BPC-157 free base is stable at room temperature for 3 weeks but is recommended to be stored desiccated below -18°C, because moisture greatly decreases the long-term stability of lyophilized peptides.2 After mixing, it reports the free base in solution is stable for 2-3 weeks at 4°C and for 3-4 months at -20°C, without naming a diluent.2
A review notes that adsorption to container surfaces is the most consequential physical degradation risk and has not been quantified.1 The label searches run for this guide returned no BPC-157 label, so no label gives storage conditions for a mixed vial.
Frequently asked questions
What strengths does BPC-157 come in?
FDA's briefing reports websites selling BPC-157 injection products of 5, 6 and 10 mg and a 10 mg per 5 mL injection kit, and an adverse event report involving a compounded 15 mg per vial injection.2 The two nominators of BPC-157 for compounding, whose nominations were later withdrawn, proposed oral capsules of 250 μg, 500 μg and 1 mg and a subcutaneous injection of 2,000 μg/mL.2
- BPC-157Half-life, evidence and status.
- BPC-157 calculatorOther vials and doses.
- Peptide groupThe group BPC-157 belongs to.
- BPC-157 and TB-500The pairing.
- How to mix KLOWA mixing guide.
- Glutathione dosageAnother dosing guide.
- Reported reactions to peptidesWhat is normal and what is not, compound by compound.
How the logged figures are counted
Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.
References
- Pharmaceutics. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. 2026. pmc.ncbi.nlm.nih.gov
- US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (BPC-157). 2026. fda.gov
- US National Library of Medicine (DailyMed). DailyMed label search for BPC-157. 2026. dailymed.nlm.nih.gov
- ClinicalTrials.gov. NCT02637284: Phase I pilot of PCO-02 (BPC-157) in healthy volunteers. 2015. clinicaltrials.gov
- Alternative Therapies in Health and Medicine. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. 2021. pubmed.ncbi.nlm.nih.gov
- Alternative Therapies in Health and Medicine. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. 2024. pubmed.ncbi.nlm.nih.gov
- Alternative Therapies in Health and Medicine. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. 2025. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT07752381: Peptide gummies containing BPC-157. 2026. clinicaltrials.gov
- ClinicalTrials.gov. NCT07437547: Phase 2 trial of BPC 157 for acute grade II hamstring strain. 2026. clinicaltrials.gov
- ClinicalTrials.gov. NCT07803250: BPC-157 after rotator cuff repair surgery. 2026. clinicaltrials.gov
- Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted